Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
Feb 01, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., Feb. 01, 2016 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its...
Sysco Reports Strong Local Case and Operating Income Growth and Delivers Diluted EPS of $0.48
Feb 01, 2016 13:00 pm UTC| Business
HOUSTON, Feb. 01, 2016 -- Sysco Corporation (NYSE:SYY) today announced financial results for its 13-week second fiscal quarter ended December 26, 2015.¹ Second Quarter Fiscal 2016 Highlights² Sales increased 0.6% to...
Genocea to Present at 2016 BIO CEO & Investor Conference
Feb 01, 2016 13:00 pm UTC| Business
CAMBRIDGE, Mass., Feb. 01, 2016 -- Genocea Biosciences, Inc.(NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief...
Feb 01, 2016 13:00 pm UTC| Business
4th vs. 3rd Quarter 2015 Highlights: Earnings of $32.0 million, or $.27 per common shareOrganic loan growth of $102.0 million, or 6.0% annualized, excluding covered loans5.3% decline in operational noninterest...
Intra-Cellular Therapies to Present at the Leerink Partners’ 5th Annual Global Healthcare Conference
Feb 01, 2016 13:00 pm UTC| Business
NEW YORK, Feb. 01, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon...
Feb 01, 2016 13:00 pm UTC| Business
BILLERICA, Mass., Feb. 01, 2016 -- American Science and Engineering, Inc. (“ASE”) (NASDAQ:ASEI) will announce its third quarter (ended December 31, 2015) fiscal year 2016 results on Monday, February 8, 2016 after the...
Oryzon Receives Approval in Spain to Initiate Phase I for ORY-2001 for Alzheimer’s Disease
Feb 01, 2016 13:00 pm UTC| Business
BARCELONA, Spain and CAMBRIDGE, Mass., Feb. 01, 2016 -- Oryzon Genomics (ISIN Code: ES0167733015), a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative...